Pharmacokinetic Characteristics Of Ezetimibe

  pharmacokinetic Characteristics of Ezetimibe 

  Patrick et the pharmacokinetic characteristics of 8 healthy male patients with oral 20mg ezetimibe Ezetimibe were studied: This product absorbs rapidly, through the portal vein enters the human liver, mainly with the dextrose glyoxylic acid to combine the glycoside, through the bile secretion into the human intestines, the combination and the Ezetimibe Ezetimibe's plasma concentration-time curve presents the multiple peaks, suggesting that there is the obvious liver circulation. Isotope Tracer showed that 78% and 11% of oral doses were excreted by feces and urine after taking ezetimibe ezetimibe 240h, the basic metabolic product in urine is also a glucose glycoside drug, which accounts for about 9% of the oral dosage, and the Ezetimibe ezetimibe, which accounts for 69% of oral doses, appears in faeces, presumably as a result of the hydrolysis of ezetimibe ezetimibe and/or a drug that has not been absorbed; Zhu and other studies found that oral ezetimibe for Ezetimibe 20mg, Tmax 9.88h, Cmax is 5. Ng Mle 1; the Tmax of glucose glycoside is 2.31h, at this time Cmax is a. 2ng Mle-1, the average AUC is $number, and 4ng H. Ml-1 is T1 2, and 19 30h of the main metabolite (glycoside ezetimibe for ezetimibe) is T1 2, This product and its metabolite completely eliminates need 100-150.

  Pharmacodynamics and pharmacokinetic studies of ezetimibe ezetimibe and various statins showed that ezetimibe ezetimibe had no effect on the pharmacokinetics of Simvastatin, Atorvastatin and lovastatin in the study. By studying the interaction between Pharmacodynamics and pharmacokinetics in 82 healthy men with oral simvastatin, 20mg and ezetimibe ezetimibe Lomg, it was found that there was no interaction between pharmacokinetics and special adverse reactions. Compared with Tanyushin, the combination of ezetimibe and ezetimibe can reduce 17 (LDI) by an extra low density lipoprotein cholesterol (p. 01). In addition, Ezetimibe ezetimibe has no significant effect on the activity of specific cytochrome P450 enzymes, suggesting that the drug interacts with other drugs that have been metabolized by P450.